Biologics in Chronic Rhinosinusitis

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-08-17 DOI:10.1016/j.iac.2024.07.005

引用次数: 0

慢性鼻炎的生物制剂：当前和未来。

慢性鼻窦炎（CRS）从表型上可分为有鼻息肉和无鼻息肉型（CRSwNP、CRSsNP）。内型根据免疫细胞活性和炎症机制将疾病分为 1 型、2 型和 3 型。研究最多的是 2 型内型，它与哮喘、特应性疾病和严重的 CRSwNP 有关。对于 CRSwNP 控制不佳的患者，目前有 3 种已获批准的生物制剂治疗方法：奥马珠单抗（omalizumab）、杜匹单抗（dupilumab）和美博利珠单抗（mepolizumab）。许多其他生物制剂正在针对 CRSwNP 和 CRSsNP 的 2 型、非 2 型和混合内型进行测试。这些研究将在塑造 CRS 管理的未来方面发挥重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.